Our location in the heart of San Diego’s thriving life sciences community means our team is made up of industry-leading experts in a range of disciplines and from a variety of backgrounds, united by a shared passion for turning science into meaningful discoveries for cancer patients.
The power to stop cancer.
The experience to know how.
The dedication to make a difference.
Dual purpose enabling a targeted medicine approach
![](/uploads/2022/03/purpose.jpg)
Part of a treatment strategy known as theragnostics, radiopharmaceuticals can be used for both therapy and diagnosis.
Radiopharmaceuticals, when tethering a radionuclide suitable for imaging, create a map of cancerous tumors in the body that provides precise diagnostic information. From the imaging results, the patients who are most likely to respond are identified and treated with individualized regiments of the therapeutic version of the same radiopharmaceutical. This precision medicine approach seeks to make substantial improvements in clinical outcomes.
Approach
![](/uploads/2022/03/tech.jpg)
![small-molecule radiopharmaceutical targeting GPCR](/uploads/2022/04/scigraphic1-1.png)
Small molecules, tethered with powerful radioisotopes, are designed to exquisitely bind to receptors overexpressed in cancer and deliver powerful radiation to kill tumors, without affecting normal tissue.
Our unique approach marries a vast knowledge of GPCR biology with unrivaled proficiency in small molecule medicinal chemistry to develop potent and highly selective radiopharmaceuticals. We take a fit-for-purpose approach, pinpointing the precise target and selecting the ideal small molecule ligand paired with the optimal radioisotope to achieve a therapeutic effect.
Novel targets for solid tumors
![GPCR family tree showing 132 peptide and protein GPCRs](/uploads/2022/04/scigraphic2.png)
![](/uploads/2022/03/novel-gray.jpg)
Largest gene family in humans
132 known protein/receptor pairs
>65 with increased tumor expression
Given GPCR overexpression in many tumors, they can be targeted in a vast range of cancer indications, from common to rare tumors.
Meet
our team
![Paul Grayson](/uploads/PaulGrayson.jpg)
![Frank Zhu headshot](/uploads/2022/03/frank-zhu.jpg)
![](/uploads/istvan-headshot-24-edit.jpg)
![Brett Ewald headshot](/uploads/2022/03/brett-ewald.jpg)
![Ana Kusnetzow](/uploads/2022/03/ana-kusnetzow.jpg)
![Umesh Gangadharmath](/uploads/2022/09/umesh.jpg)
![](/uploads/2022/04/meet-team.jpg)
Investors
![](/uploads/2022/04/board-photo.jpg)
Board
of
directors
Crinetics
Frazier Life Sciences
5AM Ventures
Boundless Bio
DCVC Bio
Radionetics Oncology
Careers
join us
![](/uploads/2022/04/joinuspic.jpg)